Pharmaceutica Analytica Acta

Flurbiprofen 8.75 mg sore throat spray: Characteristics and performance

8^th International Conference and Exhibition on Pharmaceutics & Novel Drug Delivery Systems

March 07-09, 2016 Madrid, Spain

David Veale, Adrian Shephard, Verity Adams and Charlotte Lidster

Reckitt Benckiser Health Care Ltd., Berkshire, UK
Reckitt Benckiser Health Care Ltd., Hull, UK

Posters & Accepted Abstracts: Pharm Anal Acta

Abstract:

Sore throat sprays provide targeted relief by delivering the active ingredient directly to the site of pain. Although there are several throat sprays available, they vary with respect to the spray pattern, thus affecting delivery of the active ingredient to the throat. The characteristics and performance of flurbiprofen 8.75 mg sore throat spray were compared with 12 competitor sprays. Parameters assessed include spray pattern, spray angle, droplet size, distribution, uniformity of dosage units and number of doses per bottle. Studies were conducted by an independent agency and tests were automated. The analysis showed that flurbiprofen 8.75 mg sore throat spray had the second tightest spray angle (51°), producing a more targeted dose than most competitors. Droplet size distribution studies showed flurbiprofen 8.75 mg sore throat spray had the second smallest droplet size and was therefore one of the more mistlike sprays, ensuring gentle delivery of the dose to the throat with negligible risk of aspiration into the lungs. Analysis of the spray pattern showed that the spray volume delivered, and diameter of the area covered, was uniform and consistent throughout the whole container life. Flurbiprofen 8.75 mg sore throat spray also consistently delivered an accurate dose each time. These results show that flurbiprofen 8.75 mg sore throat spray performed well overall, providing a consistent, gentle and accurate dose of medication throughout the whole container life.

Biography :

David Veale, R&D Associate at RB. BSc (Hons) in Chemistry from the University of Newcastle Upon Tyne David has worked for several years within RB across a range of R&D healthcare departments, and currently works in the Respiratory R&D team. David has experience in formulation and analysis of prescription, pharmacy and GSL medicines within the RB portfolio. His current role is innovation focussed and spans brands including Strepsils, Mucinex and Lemsip. Prior to RB, David begun his industrial career in QC analysis of the nutritional content of food products.

Email: David.Veale@rb.com